A Phase 2 interventional study of Epoetin Alfa in Anemia and Chronic Renal Insufficiency, sponsored by Ortho Biotech Products, L.P.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-19.
Sponsored by Ortho Biotech Products, L.P. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.
Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 6th largest by enrollment of the 112 interventional ones that give a count, is one of 8 that started in 2002, is one of 44 in phase 2, and was the 69th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:
Services Hospital, Lahore · Sites in Pakistan
Ages 18–65
Geoff Block
Ages 18+
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 45 · Phase 3 46 · Phase 4 20
First in 1988; this study’s year is marked. 8 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 519 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 71 across the 112 interventional studies. Of the 114 that completed or were terminated, 23 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
95 of 126 have an industry lead sponsor. The 10 most frequent:
Ortho Biotech Products, L.P. is the lead sponsor of 13 studies on the registry; none are open to participants now.
13 studies in Anemia by Ortho Biotech Products, L.P.: none open now, none under way, none of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 13 studies in Anemia by Ortho Biotech Products, L.P., this one has the largest enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2002, is one of 4 in phase 2, and was the 5th registered.
Ortho Biotech Products, L.P.’s Anemia studies by the year they started, since 2000.
2 of the studies testing Epoetin Alfa in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07565701Phase 3Geoff BlockSafety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis | 2027-04 |
| NCT07755683Services Hospital, LahoreEffect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis | 2027-02-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 126 studies testing Epoetin Alfa in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ortho Biotech Products, L.P.’s 13 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness and safety of less frequent dosing of PROCRIT (Epoetin alfa) in patients with anemia due to Chronic Kidney Disease (CKD) as assessed by hemoglobin maintenance, adverse events and health-related quality of life.
Epoetin alfa has been widely utilized as treatment for anemia associated with Chronic Kidney Disease (CKD). Epoetin alfa has been shown to increase hemoglobin (Hb) levels by an average of 1.5 g/dL to 2 g/dL in these patients over 12 weeks (Data on file Ortho Biotech Products, L.P.). This improvement in Hb levels is maintained while the patient is receiving Epoetin alfa and is associated with significant improvements in survival, exercise tolerance, and quality of life. Literature has suggested that epoetin alfa can be given less frequently and still maintain an optimal hemoglobin while also allowing patient's greater convenience. This study will further confirm that less frequent dosing of epoetin alfa is safe and effective. This is an open-label, randomized multicenter study in patients with CKD. CKD patients who are currently receiving PROCRIT therapy for at least 2 months or more and with a stable Hb (>= 11g/dL) will be randomized to one of four treatment groups. A stable Hemoglobin will be defined as a value that is ± 10% for 3 consecutive laboratory values.
This study is designed to demonstrate that there is no meaningful difference in hemoglobin level with more extended dosing regimens as compared to once weekly. A clinically meaningful difference is defined as a difference that is less than 10%. Patients will be randomized to one of 4 treatment groups: All will receive subcutaneous (under the skin) Epoetin alfa for a period of 16 weeks.
Group 1: 10,000 units every week Group 2: 20,000 units every two weeks Group 3: 30,000 units every three weeks Group 4: 40,000 units every four weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The primary efficacy variable is hemoglobin maintenance. Also, patients will be assessed for incidence and severity of adverse events and vital signs (blood pressure) during the 16 week study period.
The secondary variable is Quality of Life and Hemoglobin Change over Time
No study locations are listed for this record.
The record gives a start of Jan 2002 and a completion of Jan 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa
Ortho Biotech Products, L.P.